Studying Pregnant Women In Clinical Trials Gaining Industry Support
Executive Summary
Once seen as nearly universally forbidden, clinical trial data from the population could make up for failures of post-marketing pregnancy registries to obtain safety information.
You may also be interested in...
FDA Poised To Require More Rigorous Study Of Drug Use In Pregnancy
With new guidance expected, internal comparison groups, better protocols and potential generic industry involvement are some features that appear likely for the next generation of post-marketing requirements to assess drug safety in pregnancy.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.